News | Interventional Radiology | July 31, 2019

International Multidisciplinary Group Publishes Recommendations for Personalized HCC Treatment With Y90 TheraSphere

Hepatocellular carcinoma guidelines supported by comparative Dosisphere data, a phase II multicentric randomized dosimetry trial

International Multidisciplinary Group Publishes Recommendations for Personalized HCC Treatment With Y90 TheraSphere

July 31, 2019 — New consensus recommendations for personalized treatment for hepatocellular carcinoma (HCC) with BTG’s TheraSphere have been published by an international multidisciplinary working group1. In addition, data from the Dosisphere phase II dosimetry trial supports MAA single photon emission computed tomography (SPECT)/CT-based prospective personalized dosimetry2.

Prof. Etienne Garin, nuclear medicine physician, Cancer Centre Eugène Marquis, Rennes, France, received the gold medal at the Global Embolization Oncology Symposium Technologies (GEST) 2019 meeting for his work on the Investigator Initiated Study (IIS) Dosisphere. This study compared the efficacy of TheraSphere in 56 patients with at least one lesion > 7cm, using a personalized approach with Simplicit90Y dosimetry software versus standard dosimetry.  Higher response rates of 71 percent were seen in the personalized prospective dosimetry arm versus 36 percent with standard dosimetry. "The future for radioembolization is personalised dosimetry," said Garin, principal investigator of the study.

"The working group reached a consensus recommendation on simple, reproducible and evidence-based practice for personalized treatment of HCC patients with TheraSphere. This publication significantly advances our knowledge of dosimetry and will help to improve clinical outcomes" said Prof. Riad Salem, chief of interventional radiology, Northwestern Memorial Hospital, Chicago. The paper1 combines conclusions from the peer-reviewed literature together with expert opinion and includes curative and palliative therapy, categorized into four clinical scenarios: radiation segmentectomy, lobectomy, multifocal unilobar or bilobar disease, and HCC with macrovascular invasion. For each scenario, recommendations are provided on patient selection, treatment planning and dosimetry, treatment delivery and outcome assessment, and degree of recommendation and the strength of consensus.

Watch the VIDEO: Y90 Embolization of Liver Cancer at Henry Ford Hospital

For more information: www.therasphere.com

References

1.  Salem R, Padia S, Lam M et al. Eur J Nucl Med Mol Imaging. 2019 May 16. doi: 10.1007/s00259-019-04340-5. [Epub ahead of print]

2.  Garin E, Tselikas L, Guiu B et al. A multicentric randomised study demonstrating the impact of MAA based dosimetry on tumour response with Y90 loaded glass microsphere SIRT for HCC:  interim analysis of IIS Dosisphere [Poster presentation ECIO 2019 & oral presentation GEST 2019]

Related Content

ASG well positioned for growth as healthcare marketplace continues to evolve 

Allan Klotsche

News | Radiology Imaging | November 24, 2020
November 24, 2020 — Alpha Source Group (ASG), a comprehensive next-generation services partner, has named...
Shine Test System paired with the world’s strongest commercial fusion neutron generator manufactured by Phoenix. It can break apart low-enriched uranium to produce moly-99 for medical isotope production.

Shine Test System paired with the world’s strongest commercial fusion neutron generator manufactured by Phoenix. It can break apart low-enriched uranium to produce moly-99 for medical isotope production.

Feature | Nuclear Imaging | November 12, 2020 | By Willow Ascenzo
Medical imaging procedures such as single-photon emission computed tomography (...
Treating lung cancer patients with proton therapy may help reduce the risk of radiation-induced heart diseases, suggests a new study from Penn Medicine. In a retrospective trial of more than 200 patients, mini-strokes were significantly less common among patients who underwent proton therapy versus conventional photon-based radiation therapy. Proton therapy patients also experienced fewer heart attacks.
News | Proton Therapy | October 25, 2020
October 25, 2020 — Treating lung cancer patients with prot...
Be sure to register for the American Society for Radiation Oncology's (ASTRO) 62nd Annual Meeting, to be held October 24-28, 2020, via an interactive virtual platform. The meeting, Global Oncology: Radiation Therapy in a Changing World, will feature reports from the latest clinical trials; panels on global oncology, health disparities and the novel coronavirus; and an immersive attendee experience in a virtual convention center.
News | ASTRO | October 23, 2020
October 23, 2020 — Be sure to ...
A, Initial conventional axial CT image shows no noticeable lung damage (within red box) in right upper lobe. B, Electron density spectral CT image obtained at same time as image in A shows lesions (within red box) in right upper lobe. C, Follow-up conventional axial chest CT image obtained 5 days after images in A and B confirm presence of lesions (within red box) in right upper lobe.

A, Initial conventional axial CT image shows no noticeable lung damage (within red box) in right upper lobe. B, Electron density spectral CT image obtained at same time as image in A shows lesions (within red box) in right upper lobe. C, Follow-up conventional axial chest CT image obtained 5 days after images in A and B confirm presence of lesions (within red box) in right upper lobe. Image courtesy of the American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Coronavirus (COVID-19) | October 22, 2020
October 22, 2020 — According to an open-...
Rensselaer, First-Imaging, and GE Global researchers develop a deep neural network to perform nearly as well as more complex dual-energy CT imaging technology
News | Computed Tomography (CT) | October 20, 2020
October 20, 2020 — Bioimaging technologies are the eyes that allow doctors to see inside the body in order to diagnos